Brandon Beagle

Brandon Beagle PhD is an accomplished clinical development executive with extensive experience in oncology and cell therapy. Currently serving as Executive Director of Clinical Development at Revolution Medicines since July 2025, Brandon previously held the position of Executive Director of Clinical Science at Arcus Biosciences, leading the development of two adenosine-targeting agents from proof of concept to Phase 3 studies. Brandon's expertise includes cross-functional team leadership, strategic planning, and clinical study execution across various organizations, including Agenus and Fate Therapeutics. Educationally, Brandon holds a PhD in Cell/Cellular and Molecular Biology from the University of Alabama at Birmingham and a Bachelor’s Degree in Nutrition Sciences from California State Polytechnic University-Pomona.